ifa systems strengthens its competence team

• Felix Aaslepp as Vice President - Medical Advisor new at ifa
• as a medical practitioner Aaslepp takes over product management
• support and strengthen realization of synergies with the NEXUS Group

ifa systems AG (ISIN DE0007830788), a leading and globally active software company specializing in ophthalmology, is expanding its management team with Felix Aaslepp (36). Aaslepp, a physician with training and experience in surgery, intensive care and emergency medicine, is responsible for product management and thus for the roadmap of products and tools. Previously, he worked for a good five years in the field of pharmaceuticals and medical products with a focus on research and development and medical affairs.

"With Felix Aaslepp, we have been able to gain a new manager who not only knows the customer requirements from practical experience, but also knows the workflows as well as the legal requirements in many areas that form the framework for our software solutions," says Jörg Polis, Chairman of the Board of Management of ifa systems AG. "We are convinced that Aaslepp will make an important contribution in the future so that ifa can make the best possible use of the potential offered by digitization in the healthcare sector".

Aaslepp also sees great potential in closer cooperation with the NEXUS Group. "Together we have the possibility of offering clinics combined solutions, which maximize the strengths of both companies for the benefit of the customer. Here we have gained initial positive experience with offers for university hospitals," says Aaslepp. "ifa is the competence center for ophthalmology in the NEXUS Group. This is a good starting point for further intensifying the cooperation in the future".

Felix Aaslepp, who still occasionally takes on hospital assignments in his spare time, knows the opportunities offered by digitization in the healthcare sector first-hand. Especially in areas that offer services beyond health insurance and are managed by investors, there is a considerable need for investment to increase efficiency. "Our patient portal from Sophrona, where patients check in virtually online before visiting their practice or clinic, is still a dream of the future in the German market. But there is undoubtedly this demand, and with Sophrona we are perfectly positioned here".

In this way, ifa not only makes a technological leap in patient care, but also gradually brings about a generational change in the management team.

Contact for enquiries:
ifa systems AG
Augustinusstr. 11b
50226 Frechen
[email protected]
+49 2234 933 670

The company:

ifa systems AG (ISIN DE0007830788) is a leading global software company specializing in ophthalmology. The software is used by ophthalmologists in practices and clinics worldwide. At the heart of the products is an electronic patient record (EHR) tailored to ophthalmology, in which all data from examinations and treatments are documented. It provides interfaces and APIs in order to integrate all data from all hardware and software within the practice or clinic. In addition, it enables the integration of software solutions from external partners, such as online appointment scheduling, ERP and diagnostic systems. Thus the software became the integration platform for the practices and clinics in ophthalmology. With the acquisition of the U.S. company Soprona Inc. 2020, ifa has also secured future technology that enables genuine portal solutions for communication between doctors, patients and their partner network. In addition, ifa develops and hosts registries for care research within ophthalmology and has various specialized databases that serve research purposes. They are often also part of quality assurance or approval processes. The market for ifa's solutions is growing strongly, as digitalization in the health care system (e-health) helps to provide optimal and efficient care to patients while reducing costs. The shares of ifa systems AG are listed on the Basic Board/Open Market of the Frankfurt Stock Exchange. Nexus AG (ISIN DE0005220909) holds 52.6 % of the shares.